Hyderabad News Desk

DelveInsight’s “Gastric Cancer Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Gastric Cancer, historical and forecasted epidemiology as well as the Gastric Cancer market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Gastric Cancer market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Gastric Cancer Market Forecast

Some of the key facts of the Gastric Cancer Market Report: 

• The Gastric Cancer market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
• The American Cancer Society has predicted that there will be around 26,380 new cases of stomach cancer in the country in 2022—15,900 cases in men and 10,480 cases in women—and approximately 11,090 deaths from this form of cancer—6,690 in men and 4,400 in women
• According to Sekiguchi et al. 2022, stomach cancer has a high incidence and fatality rate in Japan and is a significant target for screening and therapy. According to the most recent figures from the cancer registry and statistics in Japan, stomach cancer ranks third in terms of cancer mortality with 42,931 deaths in 2019 and ranks second in terms of cancer incidence with 129,476 cases in 2017
• Recent GLOBOCAN data estimates that there will be 26,259 cases of gastric cancer in the United States, EU4, the United Kingdom, and Japan in 2020, correspondingly
• Most frequently affected sites in the gastrointestinal tract include the stomach (60%–75%), small bowel, ileocecal area, and rectum
• Key Gastric Cancer Companies: Amgen, Astellas, Eisai Pharma/Merck, ALX Oncology, TRANSCENTA, BeiGene, Henlix Biotech, Jiangsu Hengrui Medicine, Neovii Biotech, Eli Lilly and Company, Genmab/Janssen Biotech, Rapa Therapeutics LLC, HiberCell, Inc., and others
• Key Gastric Cancer Therapies: Bemarituzumab, Zolbetuximab, Lenvatinib, Evorpacept, TST001, Tislelizumab, HLX10, Camrelizumab, Catumaxomab, Abemaciclib, Amivantamab, RAPA-201, HC 5404 FU, and others
• The Gastric Cancer epidemiology based on gender analyzed that in developed countries, gastric cancer is 2.2 times more likely to be diagnosed in males than females
• The Gastric Cancer market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Gastric Cancer pipeline products will significantly revolutionize the Gastric Cancer market dynamics.

Gastric Cancer Overview

Gastric (stomach) cancer occurs when cancer cells form in the lining of the stomach. There are 5 layers in the stomach wall: mucosa, submucosal, muscularis propria, subserosa and serosa. The location of tumor and the layers involved play an important role in determining the stage (extent) of the cancer.

Get a Free sample for the Gastric Cancer Market Report 

https://www.delveinsight.com/report-store/gastric-cancer-market

Gastric Cancer Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Gastric Cancer Epidemiology Segmentation:

The Gastric Cancer market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

• Total Prevalence of Gastric Cancer
• Prevalent Cases of Gastric Cancer by severity
• Gender-specific Prevalence of Gastric Cancer
• Diagnosed Cases of Episodic and Chronic Gastric Cancer

Download the report to understand which factors are driving Gastric Cancer epidemiology trends @ Gastric Cancer Epidemiology Forecast

Gastric Cancer Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Gastric Cancer market or expected to get launched during the study period. The analysis covers Gastric Cancer market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Gastric Cancer Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Gastric Cancer Therapies and Key Companies

• Bemarituzumab: Amgen
• Zolbetuximab: Astellas
• Lenvatinib: Eisai Pharma/Merck
• Evorpacept: ALX Oncology
• TST001: TRANSCENTA
• Tislelizumab: BeiGene
• HLX10: Henlix Biotech
• Camrelizumab: Jiangsu Hengrui Medicine
• Catumaxomab: Neovii Biotech
• Abemaciclib: Eli Lilly and Company
• Amivantamab: Genmab/Janssen Biotech
• RAPA-201: Rapa Therapeutics LLC
• HC 5404 FU: HiberCell, Inc.

Discover more about therapies set to grab major Gastric Cancer market share @ Gastric Cancer Treatment Market

Gastric Cancer Market Strengths

• In-depth understanding of molecular heterogeneity of tumor and pathogenesis
• Scientific advances and identification of novel therapeutic targets for treatment

Gastric Cancer Market Opportunities

• Future development of potential biomarkers may improve screening and early detection of gastric cancers, with better accuracy, in the future.
• Increase in the awareness of gastric cancers and encouraging regular screening.

Scope of the Gastric Cancer Market Report

• Study Period: 2019–2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Gastric Cancer Companies: Amgen, Astellas, Eisai Pharma/Merck, ALX Oncology, TRANSCENTA, BeiGene, Henlix Biotech, Jiangsu Hengrui Medicine, Neovii Biotech, Eli Lilly and Company, Genmab/Janssen Biotech, Rapa Therapeutics LLC, HiberCell, Inc., and others
• Key Gastric Cancer Therapies: Bemarituzumab, Zolbetuximab, Lenvatinib, Evorpacept, TST001, Tislelizumab, HLX10, Camrelizumab, Catumaxomab, Abemaciclib, Amivantamab, RAPA-201, HC 5404 FU, and others
• Gastric Cancer Therapeutic Assessment: Gastric Cancer current marketed and Gastric Cancer emerging therapies
• Gastric Cancer Market Dynamics: Gastric Cancer market drivers and Gastric Cancer market barriers 
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Gastric Cancer Unmet Needs, KOL’s views, Analyst’s views, Gastric Cancer Market Access and Reimbursement 

To know more about Gastric Cancer companies working in the treatment market, visit @ Gastric Cancer Clinical Trials and Therapeutic Assessment

Table of Contents 

1. Gastric Cancer Market Report Introduction

2. Executive Summary for Gastric Cancer

3. SWOT analysis of Gastric Cancer

4. Gastric Cancer Patient Share (%) Overview at a Glance

5. Gastric Cancer Market Overview at a Glance

6. Gastric Cancer Disease Background and Overview

7. Gastric Cancer Epidemiology and Patient Population

8. Country-Specific Patient Population of Gastric Cancer 

9. Gastric Cancer Current Treatment and Medical Practices

10. Gastric Cancer Unmet Needs

11. Gastric Cancer Emerging Therapies

12. Gastric Cancer Market Outlook

13. Country-Wise Gastric Cancer Market Analysis (2019–2032)

14. Gastric Cancer Market Access and Reimbursement of Therapies

15. Gastric Cancer Market Drivers

16. Gastric Cancer Market Barriers

17.  Gastric Cancer Appendix

18. Gastric Cancer Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services